Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Files

hdl_141928.pdf (2.58 MB)
  (Published version)

Date

2024

Authors

Mackintosh, J.A.
Keir, G.
Troy, L.K.
Holland, A.E.
Grainge, C.
Chambers, D.C.
Sandford, D.
Jo, H.E.
Glaspole, I.
Wilsher, M.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Respirology, 2024; 29(2):105-135

Statement of Responsibility

John A. Mackintosh, Gregory Keir, Lauren K. Troy, Anne E. Holland, Christopher Grainge, Daniel C. Chambers, Debra Sandford, Helen E. Jo, Ian Glaspole, Margaret Wilsher, Nicole S. L. Goh, Paul N. Reynolds, Sally Chapman, Steven E. Mutsaers, Sally de Boer, Susanne Webster, Yuben Moodley, Tamera J. Corte

Conference Name

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

License

Call number

Persistent link to this record